Ovidrel (choriogonadotropin alfa)
Human Chorionic Gonadotropin (hCG) Subcutaneous Syringe (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Choriogonadotropin alfa, a biosynthetic (recombinant DNA-derived) form of human chorionic gonadotropin (hCG), is a gonad-stimulating polypeptide hormone.
Choriogonadotropin alfa, a biosynthetic (recombinant DNA-derived) form of the human chorionic gonadotropin (hCG) secreted by the placenta and derived from the urine of pregnant women, is a gonad-stimulating polypeptide hormone. Choriogonadotropin alfa is prepared from cultures of genetically modified mammalian (Chinese hamster ovary) cells using recombinant DNA technology. Like the human pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), choriogonadotropin alfa is a glycoprotein composed of nonidentical and noncovalently linked alpha and beta subunits.
The alpha-subunit of the drug has an amino acid sequence identical to that of endogenous hCG, FSH, and LH. Recombinant choriogonadotropin alfa differs from urinary-derived hCG principally in the composition of the carbohydrate moieties (e.g., branching and salicylation of oligosaccharides).
Choriogonadotropin alfa, an analog of LH, has physicochemical, immunologic, and biologic activities comparable to those of urinary-derived hCG. In pregnancy, endogenous hCG maintains the viability of the corpus luteum, which provides for the continued secretion of estrogen and progesterone necessary in the first trimester of pregnancy. In infertile women receiving a follicle-stimulating agent (e.g., FSH), choriogonadotropin alfa substitutes for the endogenous LH surge responsible for ovulation and stimulates late maturation of the ovarian follicle, resumption of oocytic meiosis, initiation of rupture of the preovulatory ovarian follicle, and luteinization of follicular granulosa cells of the ovary (as indicated by an increase in serum progesterone concentrations).
Choriogonadotropin alfa is used as a component of infertility regimens (e.g., consisting of a gonadotropin-releasing hormone agonist and follicle-stimulating hormone (FSH)) to induce final follicular maturation and early luteinization in ovulatory women undergoing controlled ovarian hyperstimulation during assisted reproductive technology (ART) programs such as in vitro fertilization and embryo transfer. The drug also is used in conjunction with follicle-stimulating hormones to induce ovulation and pregnancy in anovulatory, infertile women in whom the cause of anovulation is functional (i.e., secondary to pituitary insufficiency) and not due to primary ovarian failure.
Generic name: choriogonadotropin alfa
Pronunciation: (KOR-ee-o-goe-nad-oh-troe-pin AL-fa)
Drug class: Human Chorionic Gonadotropin (hCG)
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ovidrel
Indications
The following indications are listed for Ovidrel:
- Follicle Stimulation For Assisted Fertilization Procedure
- Ovarian Follicle Maturation Induction
Also known as: Multifollicular Development For Assisted Reproductive Technologies.
Dosing
No dosing information is available for this tab.
Choriogonadotropin alfa is administered by subcutaneous injection only. Choriogonadotropin alfa may be self-administered by the patient, who should be given instructions regarding injection of the drug.
For subcutaneous administration, the appropriate dose should be injected directly using the commercially available prefilled syringe.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Ovidrel 250 Mcg/0.5 Ml Syrg | Maintenance | Inject 0.5 milliliter (250 mcg) by subcutaneous route once daily for 1 day. |
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to human chorionic gonadotropin preparations (including urinary-derived HCG) or any ingredient in the formulations. Primary ovarian failure; uncontrolled thyroid or adrenal dysfunction; uncontrolled organic intracranial lesions such as pituitary tumors; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement of undetermined origin; sex-hormone dependent tumors of the reproductive tract and accessory organs; and pregnancy.
- Abnormal uterine bleeding
- Carcinoma of breast
- Malignant neoplasm of the ovary
- Malignant neoplasm of the uterus
- Ovarian cyst
- Pituitary neoplasm
- Pregnancy
- Primary ovarian failure
- Ovarian hyperstimulation
- Thromboembolic disorder
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects occurring in 2% or more of patients receiving choriogonadotropin alfa include injection site disorders (i.e., pain, bruising), abdominal pain, nausea, vomiting, or postoperative pain occurred during ART programs. Injection site disorders (i.e., pain, inflammation, bruising, injection site reaction), ovarian cysts, ovarian hyperstimulation, or abdominal pain occurred during ovulation induction treatment.
Less Frequent
- Ovarian cyst
- Ovarian hyperstimulation syndrome
Rare or Very Rare
- Anaphylaxis
- Thromboembolic disorder
More Frequent
- Injection site sequelae
Less Frequent
- Abdominal pain with cramps
- Nausea
- Vomiting
Rare or Very Rare
- Skin rash
Precautions
No enhanced messaging available.
Safety and efficacy not established.
Category X. (See Users Guide.)
Not known whether choriogonadotropin alfa is distributed in milk. Caution is advised if the drug is administered in nursing women.
Safety and efficacy not established.
ICD codes
| Code | Type | Description |
|---|---|---|
| Follicle stimulation for assisted fertilization procedure | ||
| Z31.83 | ICD10CM | Encounter for assisted reproductive fertility procedure cycle |
| Z31.89 | ICD10CM | Encounter for other procreative management |
| Z52.81 | ICD10CM | Egg (oocyte) donor |
| Z52.810 | ICD10CM | Egg (oocyte) donor under age 35, anonymous recipient |
| Z52.811 | ICD10CM | Egg (oocyte) donor under age 35, designated recipient |
| Z52.812 | ICD10CM | Egg (oocyte) donor age 35 and over, anonymous recipient |
| Z52.813 | ICD10CM | Egg (oocyte) donor age 35 and over, designated recipient |
| Z52.819 | ICD10CM | Egg (oocyte) donor, unspecified |
| Ovarian follicle maturation induction | ||
| Z31.83 | ICD10CM | Encounter for assisted reproductive fertility procedure cycle |
| Z31.89 | ICD10CM | Encounter for other procreative management |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.